Philippe Corcia

Philippe Corcia

Professor of Neurology

Philippe Corcia is Professor of Neurology and responsible for the ALS Center of the CHU of Tours. This is the only center of the Loire Valley area: in this center, more than 90 new cases are diagnosed every year and the cohort of ALS patients currently exceeds 240 patients. Philippe Corcia is member of the French Neurological Society (SFN), of the European Academy of Neurology and of the panel of the ALS of fronto temporal dementia. He is also member of the ENCALS and TRICALS board and of the Editorial Board of the ALS FTD Journal. He is involved in the scientific committee of the French ALS network (FILSLAN). He was the principal investigator of several clinical trials over the last five years. His field of research is mainly focused on genetic factors and metabolomics in ALS. He is member of the Inserm Unit U1253 iBrain. He signed or co-signed more than 200 publications which mainly dealt with ALS or motor neuron disorders.

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Active
Phase iii

ADORE trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more